

Martin R Stockler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8997288/publications.pdf>

Version: 2024-02-01

109
papers

5,305
citations

109321

35
h-index

95266

68
g-index

111
all docs

111
docs citations

111
times ranked

7721
citing authors

#	ARTICLE	IF	CITATIONS
1	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131.	27.0	982
2	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3191-3198.	1.6	370
3	The importance of patient-reported outcomes in clinical trials and strategies for future optimization. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 353-367.	1.2	295
4	Bisphosphonates for breast cancer. , 2005, , CD003474.		205
5	Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 3277-3283.	1.6	193
6	Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1309-1316.	1.6	154
7	Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4498-4504.	1.6	131
8	Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. <i>Lancet Oncology</i> , The, 2007, 8, 603-612.	10.7	127
9	How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 456-463.	1.6	122
10	Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. <i>Supportive Care in Cancer</i> , 2006, 14, 999-1011.	2.2	121
11	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1379-1388.	10.7	119
12	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. <i>Lancet Oncology</i> , The, 2020, 21, 1213-1223.	10.7	109
13	Bisphosphonates and other bone agents for breast cancer. , 2012, , CD003474.		98
14	Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. <i>Cancer Research</i> , 2009, 69, 7696-7703.	0.9	94
15	Assessing Quality of Life During Chemotherapy for Pleural Mesothelioma: Feasibility, Validity, and Results of Using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. <i>Journal of Clinical Oncology</i> , 2004, 22, 3172-3180.	1.6	91
16	Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review. <i>BMJ Open</i> , 2016, 6, e010938.	1.9	87
17	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4064-4075.	1.6	78
18	Evidence-based medicine: useful tools for decision making. <i>Medical Journal of Australia</i> , 2001, 174, 248-253.	1.7	75

#	ARTICLE	IF	CITATIONS
19	Responsiveness to Change in Health-Related Quality of Life in a Randomized Clinical Trial: A Comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with Analogous Scales from the EORTC QLQ-C30 and a Trial Specific Module. <i>Journal of Clinical Epidemiology</i> , 1998, 51, 137-145.	5.0	72
20	Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1253-1262.	6.3	64
21	Health Status Rated With the Medical Outcomes Study 36-Item Short-Form Health Survey After Spinal Cord Injury. <i>Archives of Physical Medicine and Rehabilitation</i> , 2005, 86, 2290-2295.	0.9	63
22	A Randomized Controlled Trial of a Standardized Educational Intervention for Patients with Cancer Pain. <i>Journal of Pain and Symptom Management</i> , 2010, 40, 49-59.	1.2	62
23	Convergent Discriminative, and Predictive Validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Assessment and Comparison with Analogous Scales From the EORTC QLQ-C30 and a Trial-Specific Module. <i>Journal of Clinical Epidemiology</i> , 1999, 52, 653-666.	5.0	59
24	What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?. <i>Lancet Oncology</i> , The, 2005, 6, 581-588.	10.7	59
25	The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. <i>Journal of Cancer Survivorship</i> , 2016, 10, 223-233.	2.9	57
26	Patients' preferences for chemotherapy in non-small-cell lung cancer: A systematic review. <i>Lung Cancer</i> , 2010, 69, 141-147.	2.0	55
27	Use of tamoxifen in advanced-stage hepatocellular carcinoma. <i>Cancer</i> , 2005, 103, 1408-1414.	4.1	54
28	A randomised controlled trial of an advance care planning intervention for patients with incurable cancer. <i>British Journal of Cancer</i> , 2018, 119, 1182-1190.	6.4	54
29	A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. <i>Lung Cancer</i> , 2013, 81, 422-427.	2.0	51
30	Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia?. <i>Pharmacoeconomics</i> , 2010, 28, 463-475.	3.3	47
31	Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. <i>Psycho-Oncology</i> , 2007, 16, 48-59.	2.3	46
32	Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 270-281.	5.0	46
33	Certain Death in Uncertain Time: Informing Hope by Quantifying a Best Case Scenario. <i>Journal of Clinical Oncology</i> , 2010, 28, 2802-2804.	1.6	44
34	Validity, Responsiveness, and Minimal Important Difference for the SF-6D Health Utility Scale in a Spinal Cord Injured Population. <i>Value in Health</i> , 2008, 11, 680-688.	0.3	43
35	Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. <i>BJU International</i> , 2013, 111, 977-983.	2.5	43
36	The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates. <i>Journal of Clinical Oncology</i> , 2013, 31, 3565-3571.	1.6	43

#	ARTICLE	IF	CITATIONS
37	Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARC Toxicity Score with oncologists' estimates of toxicity based on clinical judgement. <i>Journal of Geriatric Oncology</i> , 2019, 10, 202-209.	1.0	40
38	Preferences for Immunotherapy in Melanoma: A Systematic Review. <i>Annals of Surgical Oncology</i> , 2020, 27, 571-584.	1.5	36
39	Sentinel-Lymph-Node-Based Management or Routine Axillary Clearance? Five-Year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial: Assessment and Incidence of True Lymphedema. <i>Annals of Surgical Oncology</i> , 2017, 24, 1064-1070.	1.5	33
40	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. <i>Contemporary Clinical Trials</i> , 2021, 108, 106482.	1.8	33
41	Predicting the Toxicity of Weekly Docetaxel in Advanced Cancer. <i>Clinical Pharmacokinetics</i> , 2006, 45, 611-622.	3.5	32
42	Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom Benefit Study. <i>Oncologist</i> , 2013, 18, 1221-1228.	3.7	30
43	Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit With Chemotherapy for Symptomatic Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 865-873.	2.5	30
44	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 837-846.	1.6	29
45	Quality of life and adjuvant systemic therapy for early-stage breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1123-1134.	2.4	28
46	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 80, 275-279.	1.9	28
47	Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e204-e216.	2.9	27
48	Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. <i>European Urology</i> , 2019, 76, 306-312.	1.9	26
49	Thinking and Talking About Life Expectancy in Incurable Cancer. <i>Seminars in Oncology</i> , 2011, 38, 380-385.	2.2	25
50	Societal perspective on access to publicly subsidised medicines: A cross sectional survey of 3080 adults in Australia. <i>PLoS ONE</i> , 2017, 12, e0172971.	2.5	24
51	Measuring men's opinions of prostate needle biopsy. <i>ANZ Journal of Surgery</i> , 2005, 75, 662-664.	0.7	23
52	The administration of patient-reported outcome questionnaires in cancer trials: Interviews with trial coordinators regarding their roles, experiences, challenges and training. <i>Contemporary Clinical Trials Communications</i> , 2018, 9, 23-32.	1.1	23
53	Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. <i>EBioMedicine</i> , 2021, 72, 103625.	6.1	23
54	The benefits and costs of tamoxifen for breast cancer prevention. <i>Australian and New Zealand Journal of Public Health</i> , 2003, 27, 34-40.	1.8	22

#	ARTICLE	IF	CITATIONS
55	Sentinel Lymph Node Based Management or Routine Axillary Clearance? Three-year Outcomes of the RACS Sentinel Node Biopsy Versus Axillary Clearance (SNAC) 1 Trial. <i>Annals of Surgical Oncology</i> , 2015, 22, 17-23.	1.5	22
56	Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. <i>Patient Education and Counseling</i> , 2008, 72, 239-245.	2.2	21
57	Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis. <i>Medical Journal of Australia</i> , 2013, 198, 546-550.	1.7	20
58	Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial. <i>British Journal of Cancer</i> , 2016, 115, 1179-1185.	6.4	19
59	Patients' preferred and perceived roles in making decisions about adjuvant chemotherapy for non-small-cell lung cancer. <i>Lung Cancer</i> , 2016, 95, 8-14.	2.0	18
60	Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile?. <i>Lung Cancer</i> , 2011, 72, 213-218.	2.0	17
61	Why Is Management of Cancer Pain Still a Problem?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1907-1908.	1.6	16
62	Barriers to radiotherapy utilisation in New South Wales Australia: Health professionals' perceptions of impacting factors. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 535-541.	1.8	16
63	What is access to radiation therapy? A conceptual framework and review of influencing factors. <i>Australian Health Review</i> , 2016, 40, 11.	1.1	15
64	An Updated Systematic Review of Quantitative Studies Assessing Anxiety, Depression, Fear of Cancer Recurrence or Psychological Distress in Testicular Cancer Survivors. <i>Cancer Management and Research</i> , 2021, Volume 13, 3803-3816.	1.9	15
65	Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). <i>Breast Cancer Research and Treatment</i> , 2009, 117, 99-109.	2.5	14
66	Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. <i>BJU International</i> , 2013, 112, E35-43.	2.5	14
67	Factors influencing the use of RT in NSW: A qualitative study exploring consumer and health professional perspectives. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 625-632.	1.8	13
68	Regional Variation in Identified Cancer Care Needs of Early-Career Oncologists in China, India, and Pakistan. <i>Oncologist</i> , 2015, 20, 532-538.	3.7	12
69	Deriving a Patient-Based Utility Index from a Cancer-Specific Quality of Life Questionnaire. <i>Value in Health</i> , 2009, 12, 800-807.	0.3	11
70	Patient-Reported Outcomes Associated with Treatments for Testicular Cancer: A Systematic Review. <i>Patient Related Outcome Measures</i> , 2021, Volume 12, 129-171.	1.2	10
71	Community views on factors affecting medicines resource allocation: cross-sectional survey of 3080 adults in Australia. <i>Australian Health Review</i> , 2019, 43, 254.	1.1	9
72	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1772-1782.	1.6	9

#	ARTICLE	IF	CITATIONS
73	Development and piloting of a decision aid for women considering participation in the Sentinel Node Biopsy versus Axillary Clearance 2 breast cancer trial. <i>Clinical Trials</i> , 2015, 12, 409-417.	1.6	8
74	Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e233-e242.	1.9	8
75	Estimating survival time in older adults receiving chemotherapy for advanced cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 617-625.	1.0	8
76	Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners. <i>Patient</i> , 2021, 14, 635-647.	2.7	8
77	Students' PEARLS: successfully incorporating evidence-based medicine in medical students' clinical attachments. <i>Evidence-Based Medicine</i> , 2009, 14, 98-99.	0.6	7
78	Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020). <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	7
79	Patients'™ experiences of high-dose-rate brachytherapy boost for prostate cancer using an inpatient protocol. <i>Brachytherapy</i> , 2011, 10, 395-400.	0.5	6
80	Oncologists' perceptions on the usefulness of geriatric assessment measures and the CARG toxicity score when prescribing chemotherapy for older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 210-215.	1.0	6
81	Methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 11-11.	1.6	6
82	â€Painâ€free TRUS Bâ€™™: a phase 3 doubleâ€blind placeboâ€controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonographyâ€guided prostate biopsy (ANZUP 1501). <i>BJU International</i> , 2022, 129, 591-600.	2.5	5
83	Preliminary Validation of an Optimally Weighted Patient-Based Utility Index by Application to Randomized Trials in Breast Cancer. <i>Value in Health</i> , 2009, 12, 967-976.	0.3	4
84	Discussing Prognosis, Preferences, and End-of-Life Care in Advanced Cancer. <i>JAMA Oncology</i> , 2019, 5, 788.	7.1	4
85	Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 55-67.	1.1	3
86	Patient-reported outcomes of prostate high-dose-rate brachytherapy boost comparing an outpatient and inpatient protocol: A two-center chronologic cohort study. <i>Brachytherapy</i> , 2011, 10, 454-460.	0.5	3
87	Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews. <i>BMC Cancer</i> , 2021, 21, 1014.	2.6	3
88	TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5007-5007.	1.6	3
89	Fulvestrant: spreading the word, but not too thinly. <i>Lancet, The</i> , 2003, 362, 1254.	13.7	2
90	Students'™ PEARLS: successfully incorporating evidence-based medicine in medical students'™ clinical attachments. <i>Annals of Internal Medicine</i> , 2009, 150, JC4.	3.9	2

#	ARTICLE	IF	CITATIONS
91	Individual patient meta-analysis: Taxane plus anthracycline reduces mortality from early breast cancer. <i>Annals of Internal Medicine</i> , 2012, 156, JC6.	3.9	2
92	Patients' preferences for adjuvant sorafenib after resection of intermediate or high-risk renal cell carcinoma in the SORCE trial: What makes it worthwhile?. <i>Journal of Clinical Oncology</i> , 2015, 33, 415-415.	1.6	2
93	Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa107.	2.9	2
94	Intermittent and continuous androgen deprivation did not differ for mortality after radiotherapy for prostate cancer. <i>Annals of Internal Medicine</i> , 2013, 158, JC9.	3.9	1
95	Tamoxifen for hepatocellular carcinoma. <i>The Cochrane Library</i> , 2020, 2020, CD001024.	2.8	1
96	Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma (aRCC): EVERSUN ANZUP trial 0901.. <i>Journal of Clinical Oncology</i> , 2014, 32, 428-428.	1.6	1
97	Screen failure rates in contemporary phase II/III therapeutic trials in genitourinary malignancies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 176-176.	1.6	1
98	Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥ 3 lines of chemotherapy (PPS ≥ 3)â€”The Gynecologic Cancer Intergroup (GCI) Symptom Benefit Study (SBS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5536-5536.	1.6	1
99	Estimating prognosis in advanced cancer: Time to embrace uncertainty. <i>Journal of Geriatric Oncology</i> , 2022, 13, 389-390.	1.0	1
100	Reply to A.D. Sasse et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e254-e254.	1.6	0
101	Life After Adjuvant Chemotherapy for Breast Cancer: The News Is Mostly Good. <i>Journal of Clinical Oncology</i> , 2011, 29, 1092-1093.	1.6	0
102	Valuing the benefits of new anticancer drugs. <i>Medical Journal of Australia</i> , 2016, 204, 403-405.	1.7	0
103	EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901).. <i>Journal of Clinical Oncology</i> , 2014, 32, 438-438.	1.6	0
104	Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 44-44.	1.6	0
105	Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS5078-TPS5078.	1.6	0
106	Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS5077-TPS5077.	1.6	0
107	Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCI) Symptom Benefit Study (SBS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5564-5564.	1.6	0
108	The impact of chemotherapy on cognition: A longitudinal study in testicular cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 487-487.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Reply to L. Marandino et al. Journal of Clinical Oncology, 2022, , JCO2200497.	1.6	0